Medical - Healthcare Information Services
Compare Stocks
4 / 10Stock Comparison
DH vs DBVT vs VEEV vs ALKS
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Healthcare Information Services
Biotechnology
DH vs DBVT vs VEEV vs ALKS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Biotechnology | Medical - Healthcare Information Services | Biotechnology |
| Market Cap | $96M | $1712.35T | $27.35B | $5.90B |
| Revenue (TTM) | $238M | $0.00 | $3.20B | $1.56B |
| Net Income (TTM) | $-170M | $-168M | $909M | $153M |
| Gross Margin | 76.0% | — | 75.5% | 65.4% |
| Operating Margin | -15.6% | — | 28.7% | 12.3% |
| Forward P/E | 5.5x | — | 19.0x | 24.8x |
| Total Debt | $178M | $22M | $96M | $70M |
| Cash & Equiv. | $164M | $194M | $1.42B | $1.12B |
DH vs DBVT vs VEEV vs ALKS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Definitive Healthca… (DH) | 100 | 2.2 | -97.8% |
| DBV Technologies S.… (DBVT) | 100 | 40.8 | -59.2% |
| Veeva Systems Inc. (VEEV) | 100 | 58.4 | -41.6% |
| Alkermes plc (ALKS) | 100 | 114.8 | +14.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DH vs DBVT vs VEEV vs ALKS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DH is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 0 yrs, beta 1.71, yield 3.2%
- Lower P/E (5.5x vs 24.8x)
- 3.2% yield; the other 3 pay no meaningful dividend
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs DH's -66.1%
VEEV carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 16.3%, EPS growth 25.9%, 3Y rev CAGR 14.0%
- 5.2% 10Y total return vs ALKS's -11.0%
- Lower volatility, beta 0.77, Low D/E 1.3%, current ratio 4.89x
- Beta 0.77, current ratio 4.89x
ALKS lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.3% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (5.5x vs 24.8x) | |
| Quality / Margins | 28.4% margin vs DH's -71.5% | |
| Stability / Safety | Beta 0.77 vs DH's 1.71, lower leverage | |
| Dividends | 3.2% yield; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +110.4% vs DH's -66.1% | |
| Efficiency (ROA) | 11.1% ROA vs DBVT's -89.0% |
DH vs DBVT vs VEEV vs ALKS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
DH vs DBVT vs VEEV vs ALKS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
VEEV leads in 1 of 6 categories
DH leads 1 • DBVT leads 1 • ALKS leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
VEEV leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
VEEV and DBVT operate at a comparable scale, with $3.2B and $0 in trailing revenue. VEEV is the more profitable business, keeping 28.4% of every revenue dollar as net income compared to DH's -71.5%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $238M | $0 | $3.2B | $1.6B |
| EBITDAEarnings before interest/tax | $9M | -$112M | $956M | $212M |
| Net IncomeAfter-tax profit | -$170M | -$168M | $909M | $153M |
| Free Cash FlowCash after capex | $37M | -$151M | $1.4B | $392M |
| Gross MarginGross profit ÷ Revenue | +76.0% | — | +75.5% | +65.4% |
| Operating MarginEBIT ÷ Revenue | -15.6% | — | +28.7% | +12.3% |
| Net MarginNet income ÷ Revenue | -71.5% | — | +28.4% | +9.8% |
| FCF MarginFCF ÷ Revenue | +15.6% | — | +43.7% | +25.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -5.5% | — | +16.0% | +28.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -38.9% | +91.5% | +23.9% | -4.1% |
Valuation Metrics
DH leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 24.8x trailing earnings, ALKS trades at a 20% valuation discount to VEEV's 30.9x P/E. On an enterprise value basis, DH's 7.3x EV/EBITDA is more attractive than VEEV's 28.4x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $96M | $1712.35T | $27.4B | $5.9B |
| Enterprise ValueMkt cap + debt − cash | $111M | $1712.35T | $26.0B | $4.9B |
| Trailing P/EPrice ÷ TTM EPS | -0.71x | -0.76x | 30.92x | 24.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 5.50x | — | 18.98x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 1.70x | — |
| EV / EBITDAEnterprise value multiple | 7.25x | — | 28.40x | 17.25x |
| Price / SalesMarket cap ÷ Revenue | 0.40x | — | 8.56x | 4.00x |
| Price / BookPrice ÷ Book value/share | 0.26x | 0.66x | 3.89x | 3.28x |
| Price / FCFMarket cap ÷ FCF | 2.60x | — | 19.33x | 12.28x |
Profitability & Efficiency
Evenly matched — VEEV and ALKS each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
VEEV delivers a 13.4% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-130 for DBVT. VEEV carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to DH's 0.47x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -48.1% | -130.2% | +13.4% | +8.8% |
| ROA (TTM)Return on assets | -24.5% | -89.0% | +11.1% | +5.4% |
| ROICReturn on invested capital | -2.7% | — | +12.9% | +18.9% |
| ROCEReturn on capital employed | -2.7% | -145.7% | +13.8% | +14.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.47x | 0.13x | 0.01x | 0.04x |
| Net DebtTotal debt minus cash | $14M | -$172M | -$1.3B | -$1.0B |
| Cash & Equiv.Liquid assets | $164M | $194M | $1.4B | $1.1B |
| Total DebtShort + long-term debt | $178M | $22M | $96M | $70M |
| Interest CoverageEBIT ÷ Interest expense | -5.53x | -189.82x | — | 32.30x |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $213 for DH. Over the past 12 months, DBVT leads with a +110.4% total return vs DH's -66.1%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs DH's -54.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -61.2% | +4.9% | -23.4% | +25.3% |
| 1-Year ReturnPast 12 months | -66.1% | +110.4% | -29.4% | +16.5% |
| 3-Year ReturnCumulative with dividends | -90.8% | +19.7% | -5.2% | +14.5% |
| 5-Year ReturnCumulative with dividends | -97.9% | -69.1% | -35.3% | +60.9% |
| 10-Year ReturnCumulative with dividends | -97.9% | -87.0% | +519.4% | -11.0% |
| CAGR (3Y)Annualised 3-year return | -54.9% | +6.2% | -1.8% | +4.6% |
Risk & Volatility
Evenly matched — VEEV and ALKS each lead in 1 of 2 comparable metrics.
Risk & Volatility
VEEV is the less volatile stock with a 0.77 beta — it tends to amplify market swings less than DH's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs DH's 19.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.71x | 1.26x | 0.77x | 1.06x |
| 52-Week HighHighest price in past year | $4.70 | $26.18 | $310.50 | $36.60 |
| 52-Week LowLowest price in past year | $0.90 | $7.53 | $148.05 | $25.17 |
| % of 52W HighCurrent price vs 52-week peak | +19.6% | +76.3% | +54.2% | +96.7% |
| RSI (14)Momentum oscillator 0–100 | 40.5 | 48.1 | 49.6 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 317K | 252K | 2.3M | 2.3M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: DH as "Hold", DBVT as "Buy", VEEV as "Buy", ALKS as "Buy". Consensus price targets imply 239.5% upside for DH (target: $3) vs 24.3% for ALKS (target: $44). DH is the only dividend payer here at 3.20% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $3.13 | $46.33 | $280.10 | $44.00 |
| # AnalystsCovering analysts | 15 | 15 | 42 | 28 |
| Dividend YieldAnnual dividend ÷ price | +3.2% | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | — | 0 |
| Dividend / ShareAnnual DPS | $0.03 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +51.3% | 0.0% | +0.6% | +0.5% |
VEEV leads in 1 of 6 categories (Income & Cash Flow). DH leads in 1 (Valuation Metrics). 2 tied.
DH vs DBVT vs VEEV vs ALKS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DH or DBVT or VEEV or ALKS a better buy right now?
For growth investors, Veeva Systems Inc.
(VEEV) is the stronger pick with 16. 3% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DH or DBVT or VEEV or ALKS?
On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.
8x versus Veeva Systems Inc. at 30. 9x. On forward P/E, Definitive Healthcare Corp. is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — DH or DBVT or VEEV or ALKS?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -97. 9% for Definitive Healthcare Corp. (DH). Over 10 years, the gap is even starker: VEEV returned +519. 4% versus DH's -97. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DH or DBVT or VEEV or ALKS?
By beta (market sensitivity over 5 years), Veeva Systems Inc.
(VEEV) is the lower-risk stock at 0. 77β versus Definitive Healthcare Corp. 's 1. 71β — meaning DH is approximately 120% more volatile than VEEV relative to the S&P 500. On balance sheet safety, Veeva Systems Inc. (VEEV) carries a lower debt/equity ratio of 1% versus 47% for Definitive Healthcare Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — DH or DBVT or VEEV or ALKS?
By revenue growth (latest reported year), Veeva Systems Inc.
(VEEV) is pulling ahead at 16. 3% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Definitive Healthcare Corp. grew EPS 63. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, VEEV leads at 14. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DH or DBVT or VEEV or ALKS?
Veeva Systems Inc.
(VEEV) is the more profitable company, earning 28. 4% net margin versus -57. 5% for Definitive Healthcare Corp. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VEEV leads at 28. 7% versus -8. 5% for DH. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DH or DBVT or VEEV or ALKS more undervalued right now?
On forward earnings alone, Definitive Healthcare Corp.
(DH) trades at 5. 5x forward P/E versus 19. 0x for Veeva Systems Inc. — 13. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DH: 239. 5% to $3. 13.
08Which pays a better dividend — DH or DBVT or VEEV or ALKS?
In this comparison, DH (3.
2% yield) pays a dividend. DBVT, VEEV, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is DH or DBVT or VEEV or ALKS better for a retirement portfolio?
For long-horizon retirement investors, Veeva Systems Inc.
(VEEV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77), +519. 4% 10Y return). Both have compounded well over 10 years (VEEV: +519. 4%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DH and DBVT and VEEV and ALKS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: DH is a small-cap income-oriented stock; DBVT is a mega-cap quality compounder stock; VEEV is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock. DH pays a dividend while DBVT, VEEV, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.